Curex Alternatives: Best Options for Every GLP-1 Weight Loss Use Case

What Curex Actually Offers (and Where It Falls Short)

Curex operates as a direct-to-consumer telehealth platform that connects patients with prescribers for GLP-1 receptor agonist medications. The service focuses on convenience: asynchronous consultations, home delivery, and a subscription model that bundles the provider visit with medication fulfillment. For patients who want a fast path to a GLP-1 prescription without navigating insurance, Curex fills that gap.

The model has clear trade-offs. Most cash-pay GLP-1 telehealth services, Curex included, offer limited metabolic workup before prescribing. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends baseline evaluation of HbA1c, lipid panel, hepatic function, and thyroid status before initiating GLP-1 therapy. Platforms that skip these labs may miss contraindications or comorbidities that change the risk-benefit calculation. Curex's consultation model is brief compared to platforms that require labs before prescribing. Patients with type 2 diabetes, a personal or family history of medullary thyroid carcinoma, or a history of pancreatitis need more than a questionnaire [1].

The cost structure also deserves scrutiny. Monthly fees typically range from $199 to over $499 depending on the specific GLP-1, the dose, and whether the medication is compounded or brand-name. Compounded semaglutide, which many cash-pay platforms dispense, exists in a regulatory gray zone. The FDA has stated that compounded drugs are not FDA-approved and do not undergo the same manufacturing scrutiny as commercially available products [2]. This matters when you are injecting a peptide weekly for months or years.

The Clinical Evidence Behind GLP-1 Weight Loss

Before comparing platforms, the drug data matters. Semaglutide 2.4 mg (Wegovy) produced 14.9% mean body weight reduction versus 2.4% with placebo at 68 weeks in the STEP-1 trial (N=1,961) [3]. That is roughly 34 pounds for a person starting at 230 pounds. Tirzepatide performed even more impressively: the SURMOUNT-1 trial (N=2,539) showed 15 mg tirzepatide achieved 22.5% mean weight loss at 72 weeks, with 63% of participants losing at least 20% of body weight [4].

These are large effect sizes. They also come with real adverse events. Gastrointestinal side effects (nausea, vomiting, diarrhea, constipation) affected 74.2% of semaglutide-treated patients in STEP-1, though most events were mild to moderate [3]. The SELECT cardiovascular outcomes trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease [5]. This finding earned Wegovy an expanded FDA indication for cardiovascular risk reduction.

Any platform prescribing these medications should be evaluating whether a patient is an appropriate candidate. Not just whether they meet a BMI threshold.

HealthRX: Best Alternative for Clinical Rigor

HealthRX pairs each patient with a board-certified physician who reviews comprehensive lab work before writing a GLP-1 prescription. The protocol includes baseline metabolic panels, thyroid function, renal function, and HbA1c. Follow-up labs are repeated at defined intervals during treatment, not just at initiation.

This approach aligns with how GLP-1s were studied in registration trials. The STEP program and SURMOUNT program both included extensive screening and monitoring. The American Association of Clinical Endocrinology (AACE) 2024 consensus statement recommends ongoing metabolic monitoring during anti-obesity pharmacotherapy, including assessment for lean mass preservation and nutritional deficiencies [6]. Dr. Harold Bays, AACE's chief science officer, has stated: "Anti-obesity medications are not cosmetic treatments. They require the same clinical oversight as any other chronic disease therapy" [6].

HealthRX also offers both brand-name and compounded GLP-1 options, with transparent pricing. Patients who want or need brand-name Wegovy or Zepbound get support with prior authorization. Those who choose compounded formulations receive medication from 503B-registered outsourcing facilities that operate under FDA oversight. Monthly costs are competitive with Curex but include the lab work that Curex charges extra for or omits entirely.

The platform is strongest for patients with comorbidities (type 2 diabetes, PCOS, cardiovascular disease, MASLD) where GLP-1 therapy intersects with other medical management. It is also the better fit for anyone who wants a physician, not just a prescriber.

Ro (Roman/Rory): Best for Brand Recognition and Pharmacy Integration

Ro's body program prescribes both compounded and brand-name GLP-1s through its integrated pharmacy and telehealth platform. The company has spent heavily on consumer trust-building. Its model is polished. Consultations happen via structured asynchronous messaging with a licensed provider, and medications ship from Ro's own pharmacy.

Monthly pricing for Ro's GLP-1 program starts around $145 for compounded semaglutide at introductory doses and scales to $499+ for higher doses. Brand-name medications are billed through insurance where possible. Ro's advantage is fulfillment speed and a well-designed patient portal. The limitation is similar to Curex: the clinical depth is shallow. Lab requirements are minimal, and ongoing monitoring relies primarily on patient-reported outcomes rather than objective biomarkers.

A 2023 systematic review in Obesity Reviews found that digital health interventions for obesity produce better outcomes when they include regular clinical touchpoints and biomarker tracking, not just medication access [7]. Ro fits patients who are otherwise healthy, have a straightforward obesity presentation, and want a frictionless consumer experience. For medically complex patients, it may not provide enough clinical guardrails.

Calibrate: Best for Insurance-Based Coverage

Calibrate's model differs fundamentally from cash-pay platforms. The company works with commercial insurance to cover GLP-1 medications, charging a separate program fee (typically $99 to $199/month) for its metabolic health curriculum and coaching. For patients whose insurance covers Wegovy or Zepbound, Calibrate can reduce total out-of-pocket cost significantly compared to paying cash at Curex or similar platforms.

The program is structured as a one-year metabolic reset. It includes a physician visit, metabolic labs, GLP-1 prescribing, a dedicated coach, and a curriculum covering nutrition, exercise, sleep, and emotional health. This structure maps more closely to the comprehensive lifestyle intervention that the USPSTF recommends alongside pharmacotherapy for obesity [8].

Calibrate's weakness is access speed. Insurance prior authorizations can take weeks. Not all employers or plans cover GLP-1s for obesity. And if your insurance denies coverage, Calibrate's model becomes significantly less cost-effective because you still pay the program fee on top of cash-price medication. Patients who know their plan covers anti-obesity medications should seriously evaluate Calibrate. Those with uncertain coverage may end up paying more than they would through a straightforward cash-pay platform.

Found: Best Budget Option for Coached Weight Loss

Found combines GLP-1 prescribing (where clinically appropriate) with a broader weight loss coaching model. The platform prescribes a range of medications, not just GLP-1s. Patients may receive metformin, bupropion-naltrexone, topiramate, or a GLP-1 depending on their profile and budget. Monthly membership starts at $99 before medication costs.

This flexibility is Found's advantage. Not every patient needs or can afford a GLP-1. The AACE/ACE obesity treatment algorithm positions different pharmacotherapies at different stages based on BMI, comorbidities, and prior treatment response [9]. A stepped approach, starting with less expensive agents and escalating to GLP-1s when needed, can be clinically reasonable and far more affordable.

Found's limitation is prescriber variability. The platform contracts with a large network of independent providers, and consultation quality can be inconsistent. Coaching is app-based and group-oriented rather than individualized. For cost-conscious patients who may benefit from non-GLP-1 pharmacotherapy or who want to start with a lower-cost agent before committing to injectable therapy, Found offers a practical entry point.

Henry Meds: Best for Compounded GLP-1 Price Transparency

Henry Meds is a cash-pay telehealth service that focuses almost exclusively on compounded peptide medications, including compounded semaglutide and tirzepatide. The platform has gained attention for aggressive pricing, with compounded semaglutide starting as low as $199/month at maintenance doses. This tends to undercut Curex and Ro for patients who specifically want compounded formulations.

Transparent, flat-rate pricing is the main draw. Henry Meds posts medication costs publicly rather than gating them behind a consultation. The clinical model is similar to Curex: async provider evaluation, minimal lab requirements, monthly subscription.

The same caveats about compounded medications apply here. The FDA's updated guidance on compounded semaglutide has reinforced that compounded versions are not interchangeable with FDA-approved products and may carry different safety profiles [10]. A 2024 analysis published in JAMA Network Open found significant variability in peptide content and sterility among compounded GLP-1 samples tested from multiple pharmacies [11]. Henry Meds sources from 503B facilities, but patients should understand that compounded is not the same as brand-name, regardless of the platform dispensing it.

How to Choose: Matching Platform to Patient Profile

The right alternative to Curex depends on three variables: your medical complexity, your insurance situation, and your tolerance for clinical minimalism.

If you have comorbidities like type 2 diabetes, cardiovascular disease, PCOS, or fatty liver disease, choose a platform that requires labs and provides physician-led monitoring. HealthRX is built for this. So is your existing primary care provider or endocrinologist, if they prescribe GLP-1s.

If your insurance covers anti-obesity medications and you can tolerate a prior authorization process, Calibrate's model can save you hundreds per month versus cash-pay. The STEP-1 trial's demonstrated efficacy makes a strong case for brand-name semaglutide when insurance will pay for it [3].

If cost is the primary driver and you are otherwise metabolically healthy with a straightforward obesity presentation, Henry Meds or Found may offer the lowest monthly spend. But lower cost should not mean lower oversight. The World Health Organization's 2024 guidelines on obesity management emphasize that pharmacotherapy should always be paired with lifestyle modification and clinical monitoring [12].

Dr. Robert Kushner, professor of medicine at Northwestern University Feinberg School of Medicine, has put it directly: "The biggest mistake in obesity pharmacotherapy is treating it like a prescription-only problem. The medication is one component of a comprehensive treatment plan that includes nutrition, activity, behavioral strategies, and medical monitoring" [13].

Red Flags to Watch for on Any GLP-1 Telehealth Platform

Some warning signs apply regardless of which platform you evaluate. Be cautious about any service that prescribes without asking about personal or family history of medullary thyroid carcinoma or MEN2 syndrome. Both semaglutide and tirzepatide carry boxed warnings about thyroid C-cell tumors based on rodent studies [14]. A platform that skips this screening is cutting corners on safety.

Watch for services that do not ask about concurrent medications. GLP-1 receptor agonists slow gastric emptying, which can alter absorption of oral medications including oral contraceptives, levothyroxine, and warfarin [14]. Any prescribing provider should review your full medication list.

Avoid platforms that guarantee a prescription before evaluation. No legitimate medical service can promise a specific drug before assessing the patient. If a platform's marketing says "get your GLP-1 prescription today, guaranteed," that is a compliance red flag, not a feature.

The Obesity Medicine Association's position statement on telehealth prescribing supports virtual obesity care when it includes proper medical evaluation, informed consent, and longitudinal follow-up [15]. Convenience should not replace clinical standards.

What to Ask Before Signing Up for Any Platform

Patients should ask five direct questions before choosing a GLP-1 telehealth provider. First: does the platform require labs before prescribing, and which specific tests? Second: will you see the same provider at follow-ups, or a rotating panel? Third: what happens if you experience a serious adverse event at 10 PM on a Saturday? Fourth: is the medication compounded or FDA-approved, and from which pharmacy? Fifth: what is the total monthly cost including consultation fees, medication, shipping, and any lab work?

The answers to these questions will separate platforms with genuine clinical infrastructure from those running a prescription mill with a good user interface. A 68-week commitment to weekly injections deserves the same due diligence you would give to any other chronic medication regimen.